Johnson & Johnson Innovative Medicine. "We're pleased to build on the more than a decade of research reinforcing the safety and efficacy of SPRAVATO ® and look forward to working with the FDA to ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ... to Janssen Pharmaceutical Companies of Johnson & Johnson, which developed Spravato.

Phase 4 data showed esketamine monotherapy improved symptoms in as early as 24 hours. Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of ...

Esketamine monotherapy was found to significantly improve depressive symptoms in patients with treatment-resistant depression. Johnson & Johnson is seeking to expand the approval of Spravato ...

TITUSVILLE, N.J., July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE ... seeking approval of SPRAVATO ® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment ...

2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ...

2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ...